PROSTATE CANCER: The androgen receptor remains front and centre

    loading  Checking for direct PDF access through Ovid

Abstract

Abiraterone is an androgen biosynthesis inhibitor that further lowers testosterone in men receiving standard androgen deprivation therapy for metastatic castration-resistant prostate cancer. Previously shown to improve survival in patients after treatment with docetaxel, abiraterone has demonstrated benefits in a new phase III trial in men who are chemotherapy naive.

Related Topics

    loading  Loading Related Articles